Anzeige
Mehr »
Login
Sonntag, 22.12.2024 Börsentäglich über 12.000 News von 679 internationalen Medien
Breaking News: Vorweihnachtlicher Kaufrausch an der Börse?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CRZT | ISIN: FR0013333077 | Ticker-Symbol: 0JZ
Frankfurt
20.12.24
15:29 Uhr
1,355 Euro
-0,035
-2,52 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
AFFLUENT MEDICAL SA Chart 1 Jahr
5-Tage-Chart
AFFLUENT MEDICAL SA 5-Tage-Chart
Dow Jones News
518 Leser
Artikel bewerten:
(2)

Affluent Medical: H1 2024 results

Finanznachrichten News

DJ Affluent Medical: H1 2024 results.

Affluent Medical 
Affluent Medical: H1 2024 results. 
26-Sep-2024 / 17:45 CET/CEST 
Dissemination of a French Regulatory News, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
PRESS RELEASE 
 
 
 
 
 
H1 2024 RESULTS 
   -- Major advances in all three programs 
   -- Several strategic agreements signed with the world medtech leader in cardiology 
   -- Extension of financial runway to July 2025 
 
 - Several agreements signed in July 2024 with Edwards Lifesciences for an initial amount of EUR15m and an 
  option to acquire the rights for KaliosTM 
 - Positive feedback from the Food & Drug Administration (FDA) to accelerate access to the US market for 
  KaliosTM through a simple De Novo or 510K pathway 
 - Progress in the 'Dry' pilot study with the Artus urinary sphincter, with 7 patients implanted by 
  mid-September 
 
Aix-en-Provence, September 26, 2024 - 5:45 p.m. CEST - Affluent Medical (ISIN: FR0013333077 - Ticker: AFME - 
"Affluent"), a French clinical-stage medical technology company specializing in the international development and 
industrialization of implantable innovative medical devices, is today publishing its financial results for H1 2024 and 
providing an update on its clinical and operational progress and the extension of its financial horizon until July 
2025. 
 
Strong progress with all three clinical programs 
Since January 1, 2024, Affluent Medical has taken several major steps in the development of its three medical devices. 
At the same time, and to meet its operational needs, the Company has secured several financings and signed a strategic 
partnership with the leader in this space, Edwards Lifesciences. 
 
MITRAL RING KALIOSTM: Positive feedback from the FDA to quickly access the US market 
KaliosTM is the only mitral annuloplasty device that can be simply adjusted percutaneously by a cardiologist to treat 
both residual or recurrent mitral valve insufficiency, at any time after implantation, repeatedly and with a beating 
heart, thereby avoiding a repeat open-heart surgery. Affluent Medical believes that KaliosTM would avoid further 
intervention for potentially 30% to 40% of patients over a five-year horizon. The global market for mitral valve repair 
surgery was estimated to be USD1.5 billion in the US-Europe region in 2023, growing at 3.5% per year. 
In line with the US market access strategy announced in Q3 2023, the Company made several pre-submissions to the FDA to 
assess the marketing authorization process for its medical device as a class 2 device, which is faster than the 
registration process in Europe. 
In September 2024, Affluent Medical received positive feedback from the FDA on this approach and the Agency indicated 
that no additional patients would be required beyond the 26 patients already treated in the Optimise II study. The FDA 
also shared its recommendations for the long-term follow-up of patients in preparation for the future submission. 
Affluent Medical's objective is to submit a De Novo application with current clinical data at the end of 2025/early 
2026, followed by commercial launch, subject to Edwards' decisions. 
 
 
MITRAL VALVE EPYGON: Acceleration of patient assessments and of activating clinical centers 
Epygon is the only biomimetic mitral heart valve that mimics the anatomy of the native mitral valve and physiological 
blood flow, able to be implanted via a transcatheter route. This transcatheter approach avoids an invasive open-heart 
procedure and associated complications to treat mitral valve insufficiency. 
This serious and potentially fatal disease affects 2% of the world's population, or approximately 160 million people. 
However, fewer than 4% of patients with a severe form are able to have open heart surgery, which poses a high risk of 
death and hospitalization. 
In 2024, the company began a collaboration with Prof. Mohammad Sarraf, MD, interventional cardiologist at the Mayo 
Clinic in the US, to evaluate the benefits of the biomimetic design of the Epygon valve. This innovative design aims to 
replicate the anatomy and natural physiology of the native mitral valve to enable patients to recover good cardiac 
function more quickly. 
During the first half of 2024, Affluent Medical accelerated patient evaluations, achieving a fourfold increase in the 
number of patients included by the end of June 2024. The Company has increased the number of activated centers, with 
currently 11 centers in Europe. The selection criteria for this type of clinical study are highly stringent. As a 
result, Affluent Medical continues to work to increase the number of centers and has submitted applications for five 
new centers (in Austria, Italy, Germany and Spain), with the target of activating these sites in the coming months. The 
goal is to implant up to 10 patients to complete the pilot phase. 
 
URINARY SPHINCTER ARTUS: seven patients already received implants; completion of pilot phase of study planned for Q4 
2024 
Artus is the first artificial urinary sphincter that can be activated by the patient with a simple remote control for 
the treatment of moderate to severe urinary incontinence. Urinary incontinence is a major public health problem for 
over 400 million people worldwide without any innovation in the last 40 years, causing patients to suffer a reduced 
quality of life associated with the psychological disorders related to the disease. 
In March 2024, the first implant of the Artus next-generation urinary sphincter was successfully performed by Roman 
Zachoval, MD, PhD, Head of the Department of Urology at Thomayer University Hospital in Prague, Czech Republic. 
At the end of June, the safety criteria were met in the first two patients, who did not report any discomfort or 
inconvenience during the use of the device. A performance assessment will be conducted in the pivotal phase of the 
study, evaluating reduction in urinary leakage at three months post implantation. 
 
As of mid-September 2024, seven patients had received an implant, representing over half of the planned patients for 
the pilot phase of the study. The Company plans to implant a total of 10 patients by Q4 2024 and then launch the 
pivotal phase of the study. An additional 60 patients are planned to be enrolled in the pivotal phase of the study, 
which will assess performance based on at least a 50% reduction in incontinence pads. 
 
Ongoing support from major shareholders with two successive financings 
 
EUR3.5 million capital increase subscribed by main shareholders 
 
At the end of January 2024, Affluent Medical announced the completion of a EUR3.5 million bridge financing from its main 
shareholders (Truffle Capital, LCEA, Ginko Invest, Denos and Hayk Holding), in the form of a capital increase with 
cancellation of preferential subscription rights of shareholders in favor of a category of beneficiaries. The 
transaction enables the Company to finance operations, in particular the costs related to regulatory support for 
interactions with the FDA for KaliosTM, the initiation of the pilot study for Artus and the continuation of the pilot 
study for Epygon. 
 
 
Current account advances granted by reference shareholders 
 
In April 2024, to finance its short-term operational needs, Affluent Medical carried out another bridge financing with 
its main shareholders in the amount of EUR3.5m. In the form of current account advances, the Company was able to extend 
its financial horizon until the end of July 2024 and explore various additional financing options. The shareholders 
that participated in this financing were Truffle Capital and Ginko Invest. 
 
Signing in July 2024 of several strategic agreements with Edwards Lifesciences, a global leader in innovative solutions 
for cardiovascular diseases, which becomes a reference shareholder 
 
On July 11, 2024, the Company entered into several agreements with Edwards Lifesciences relating to its interventional 
cardiology products (KaliosT adjustable mitral ring) and technologies (mitral valve technology). Under these 
agreements, Affluent Medical received an initial cash payment of EUR15 million. 
 
The three agreements break down as follows: 
   -- An initial payment of EUR5 million for an exclusive purchase option for Kephalios, the wholly owned 
  subsidiary of Affluent Medical developing the innovative adjustable mitral ring KaliosT, based on the results of 
  its clinical study. Operational activities for the development of KaliosT will continue to be managed exclusively 
  by Affluent Medical during the life of the option. 
   -- An initial payment of EUR5 million for Affluent's global, non-exclusive intellectual property license on 
  the biomimetic heart valve replacement technology. The agreement is limited to open-heart surgery, enabling 
  Affluent Medical to retain its right for the transcatheter pathway. Affluent Medical is eligible to receive future 
  royalties on all products that may be marketed using the licensed patents throughout the lifetime of these patents. 
  Affluent Medical retains all rights to the transcatheter valve patents, including those for its Epygon mitral 
  valve, which is currently in clinical development. 
   -- A EUR5 million payment as part of Edwards Lifesciences' acquisition of a stake in Affluent. Edwards 
  Lifesciences invested EUR5 million to acquire a stake in Affluent Medical, becoming a 9.21% shareholder. This 
  investment was made as part of a capital increase with cancellation of preferential subscription rights of 
  shareholders through an offer reserved for certain categories of beneficiaries. The unit subscription price, set at 
  EUR1.38 per share (including a par value of EUR0.10 and an issue premium of EUR1.28), reflected a 15% discount on the 
  weighted average price over the last 20 trading sessions before July 11, 2024. This strategic investment by Edwards 
  Lifesciences marked an important step in the development of Affluent Medical, recognizing the innovation of its 
  products. 
 
With the initial cash payment of EUR15 million received under these agreements, Affluent Medical's financial runway was 
extended by more than one year to July 2025. 
In addition to this initial payment, in accordance with the agreements, new payments could be made to Affluent, in 
particular, related to the exercise of the exclusive purchase option for Kephalios, which would be triggered based on 
the results of the ongoing Optimise II pivotal clinical study with KaliosTM, as well as royalty payments on the sales 
of surgical valves using Affluent's technology. 
 
 
 
FINANCIAL STATEMENTS FOR H1 2024 
 
The main financial items under IFRS are presented in the table below and were approved by the Board of Directors at its 
meeting on Tuesday, September 24, 2024. The Statutory Auditors conducted a limited review of the half-year financial 
statements. 
 
The full financial statements are available on the Company's website: www.affluentmedical.com. 
 
Consolidated income statement (in thousands of euros)       6/30/2024  6/30/2023 
                                 6 months  6 months 
Other operating income                      661     590 
Purchases consumed                        (918)    (1,037) 
External costs                          (3,721)   (2,828) 
Personnel expenses                        (3,691)   (2,996) 
Taxes and duties                         (36)    (49) 
Provisions net of reversals                    11     - 
Other current operating income and expenses            89     101 
Depreciation and amortization                   (1,202)   (1,206) 
 
CURRENT OPERATING INCOME                     (8,807)   (7,425) 
 
OPERATING INCOME after share of net income of equity affiliates  (8,807)   (7,425) 
Net financial income                       (638)    (633) 
Income taxes                           77     78 
NET INCOME (LOSS)                         (9,368)   (7,980) 
 
Cash flow from operating activities                (3,702)   (8,531) 
Cash flow from investing activities                (64)    (34) 
Cash flow from financing activities                3,023    12,531 
Increase (decrease) in cash                    (743)    3,966 
 
Cash and cash equivalents                     914     6,545 

During H1 2024, consumed purchases decreased by EUR119,000 compared with H1 2023, with a decrease of EUR141,000 in external study expenses.

The change in external costs between the two periods was mainly due to consulting, engineering and recruitment fees, up by EUR901,000.

The EUR405,000 increase in personnel expenses in the first half of 2024 was due to the increase in the Group's workforce in research and development, clinical activities and management functions.

The Group had an average headcount of 66 employees at the end of H1 2024, compared with 52 one year previously.

In the first half of 2024, financial income included: accrued interest of EUR618,000 on repayable advances (Mivana and PIAVE Artus); accrued interest of EUR38,000 on current account advances received in May 2024 from certain shareholders; interest paid of EUR63,000 (EUR27,000 in the first half of 2023) in connection with the pre-financing of research tax credit receivables; financial interest on leases of EUR21,000; the accretion of repayable advances in accordance with IAS 20 "Accounting for Government Grants and Disclosure of Government Assistance" of EUR7,000; and changes in the fair value of liabilities derivatives amounting to +EUR100,000 (+EUR53,000 in the first half of 2023).

The Company reported a net loss of EUR9.4 million in H1 2024, compared to a net loss of EUR8.0 million in the prior year period.

Availability of the 2024 half-year financial report

The interim financial report for 2024 is available to the public and was filed with the French Financial Markets Authority on September 26, 2024. It is also available on the company's website in the Investors section.

About Affluent Medical

Affluent Medical is a French medical technologies company, founded by Truffle Capital, that aims to become a global leader in the treatment of structural heart diseases, one of the world's leading causes of mortality, and urinary incontinence, which currently affects one in four adults.

Affluent Medical develops next-generation implants that are minimally invasive, innovative, adjustable and biomimetic, designed to restore essential physiological functions. The candidate products developed by the Company are all undergoing clinical studies in humans.

Subject to raising the funds necessary to finance its strategy and the positive results of ongoing clinical studies, the Company aims to gradually market its products from 2026, directly or indirectly.

For more information, please visit www.affluentmedical.com

Contacts:

AFFLUENT MEDICAL       SEITOSEI.ACTIFIN 
               Financial communications / Press relations 
Sébastien Ladet        Ghislaine Gasparetto / Jennifer Jullia 
Chief Executive Officer    +33 (0)6 21 10 49 24 / +33 (0)1 56 88 11 19 
investor@affluentmedical.com ghislaine.gasparetto@seitosei-actifin.com / jennifer.jullia@seitosei-actifin.com 
               MC SERVICES AG 
PRIMATICE 
               Media relations Europe 
Public Relations France 
Thomas Roborel de Climens   Caroline Bergmann / Kirsten Rühl 
+33 (0)6 78 12 97 95 
               +49 (0)211 529252 20 / +49 (0)211 529252 16 
thomasdeclimens@primatice.com 
               affluent@mc-services.eu 

-----------------------------------------------------------------------------------------------------------------------

Regulatory filing PDF file File: 20240926_PR_Affluent_Medical_H1 2024_final

=---------------------------------------------------------------------- 
Language:    English 
Company:     Affluent Medical 
         320 avenue Archimède, Les pléiades III Bâtiment B 
         13100 Aix en Provence France 
         France 
Phone:      +33 4 42 95 12 20 
E-mail:     jerome.geoffroy@affluentmedical.com 
Internet:    https://www.affluentmedical.com/ 
ISIN:      FR0013333077 
Euronext Ticker: AFME 
AMF Category:  Inside information / News release on accounts, results 
EQS News ID:   1996731 
 
End of Announcement EQS News Service 
=------------------------------------------------------------------------------------ 

1996731 26-Sep-2024 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1996731&application_name=news&site_id=dow_jones%7e%7e%7ef1066a31-ca00-4e1a-b0a4-374bd7d0face

(END) Dow Jones Newswires

September 26, 2024 11:45 ET (15:45 GMT)

© 2024 Dow Jones News
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.